ArticleCureus2026
Occult Metastatic Prostate Carcinoma Presenting With Decompensated Heart Failure and Bicytopenia.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Decompensated heart failure (DHF) may occasionally conceal an underlying systemic malignancy. Persistent hematological abnormalities, particularly thrombocytopenia and markedly elevated alkaline phosphatase (ALP), extending beyond the acute phase of illness warrant systematic evaluation for bone marrow pathology or infiltrative disease, irrespective of the presenting diagnosis. A 53-year-old man with no prior comorbidities presented with DHF, bicytopenia (anemia and thrombocytopenia), and markedly elevated ALP. He developed disseminated intravascular coagulation (DIC) during hospitalization, managed with fresh frozen plasma (FFP), platelet concentrates, and cryoprecipitate, with subsequent resolution; however, thrombocytopenia and ALP elevation persisted. Bone marrow examination revealed infiltration by metastatic adenocarcinoma. Despite comprehensive evaluation including gastrointestinal endoscopies, contrast-enhanced computed tomography (CT), and 18-fluorodeoxyglucose positron emission tomography-CT (18-FDG PET-CT), the primary site remained elusive in the setting of multiple elevated tumor markers: prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), and carbohydrate antigen (CA) 19-9. Immunohistochemistry of the bone marrow biopsy demonstrated positivity for cytokeratin (CK) and NKX3.1, establishing prostatic origin. Subsequent prostate biopsy confirmed left-lobe prostatic adenocarcinoma with a Gleason score of 4+3=7 (Grade Group 3), tumor comprising 70% of the biopsy core, and perineural invasion, consistent with high-risk locally advanced disease. The patient was commenced on androgen deprivation therapy (ADT). Persistent thrombocytopenia and markedly elevated ALP may represent the sole initial manifestation of occult metastatic prostate cancer, even in young patients with no urological symptoms. Immunohistochemistry, particularly NKX3.1, is indispensable in establishing prostatic origin when the primary site remains radiologically occult after comprehensive investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.